Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting
SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and […]
AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2019
Reports EPS of $1.71, Economic EPS of $3.16Completed investment in Garda Capital PartnersCompleted BlueMountain transaction and received approximately $90 million […]
Wanda Sports Group Appoints Kenneth Jarrett to Its Board of Directors
BEIJING, Oct. 28, 2019 (GLOBE NEWSWIRE) — Wanda Sports Group Company Limited (NASDAQ: WSG), a leading global sports events, media […]
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it […]
Orgenesis to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
GERMANTOWN, Md., Oct. 28, 2019 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and […]
Nuance Partners with The Sullivan Group to Add Emergency Medicine Guidance to Dragon Medical Advisor
BURLINGTON, Mass., and DENVER, Oct. 28, 2019 (GLOBE NEWSWIRE) — At the American College of Emergency Physicians (ACEP) conference, Nuance […]
Opera launches OLeads in Nigeria to enable growth for more than 40 million small and medium size enterprises
LAGOS, Nigeria, Oct. 28, 2019 (GLOBE NEWSWIRE) — Opera Limited (NASDAQ: OPRA), one of the world’s major browser developers and […]
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
Enrollment in MOMENTUM Phase 3 migraine trial of AXS-07 in patients with history of inadequate response nearly complete; on track […]
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~~ Achieved Site Initiation and Began […]
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
-Provides update from ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies--Began treating patients in Phase 1/2 […]
